mycetin has come out as a versatile antibiotic effective over a wide range of microbial infection. Ever broadening usage of this drug is still being explored and the full account of its activity will naturally be deferred pending collection of further evidences. Of particular interest, however, is its action against salmonella group of organism, and against almost all types of rickettsia and a section of virus like that of primary atypical pneumonia, herpes zoster and psittacosis?Lyi?iphogranuloma inguinale group. This potent antibiotic was isolated from the culture filtrate of an actinomycete, from a soil sample from Caracas, Venezuela by Ehrlich and his associates in 1947. It was shortly afterwards isolated in crystalline form by Bartz in 1948 , and it has got the unique privilege of being synthesized by commercial method (Controulis et al., 1949) .
Laboratory investigation has proved its effectiveness against most of the gram-positive and gram-negative organisms, with notable exceptions of mycobacterium and Clostridia groups. However, it is more effective in gramnegative bacteria. It is ineffective against actinomycetes, fungi, protozoa and yeast. Its effect against syphilis is doubtful.
Clinical trial in acute and chronic bronchopulmonary infections, infections of the urinary tracts, common surgical wounds and peritonitis, brucellosis, tularaemia, whooping cough and against some strain of proteus infection, was encouraging. Infection with Ps. pyocyanea is absolutely resistant to this drug.
Most impressive result of Chloromycetin is obtained in the treatment of typhoid fever which was incidentally observed by Woodward et al. (1948) in Malaya, while trying this drug in scrub typhus. Successful result of Chloromycetin consistently encountered in typhbid fever has led to its universal use and has revolutionized the treatment of this fell disease, where the physician used to be a helpless spectator throughout the whole course of illness. Like streptomycin in tuberculosis Chloromycetin in typhoid group of fevers is an absolute indica-tion, a distinction hitherto not obtained by any other major antibiotic.
Chloromycetin is effective per orally and is rapidly absorbed from the gut. Optimum concentration in the blood after a therapeutic dose remains for about 4 to 6 hours only. It passes easily the placental and brain barriers. It also pervades the body fluid like pleural and peritoneal exudates. It is poorly excreted in the bile. In infants and children it appears to be effective when given rectally in higher dosage. Within (Yolini et al., 1950) . In one case agranulocytosis has been reported.
The mode of action of Chloromycetin is not definitely known. Probably it is a bacteriostatic agent. Smith et al. (1949) suggested that it inhibits the esterase system of enzyme present in the bacteria. Resistant strains due to habituation of the bacteria are not likely to impair the usefulness of this drug.
Versatile as the action of Chloromycetin on the microbial world is the effective dose also varies in different diseases. In general it can be said that 50 mg. per kg.* of body weight per day in divided doses, until the signs and symptoms of the disease are controlled, is the optimum dose in most of the cases. Afterwards at a reduced dose it may be continued for few more days. In children the dose is usually slightly higher (75 to 100 mg. per kg. of body weight) and well tolerated. In chronic pulmonary infection, infection of the urinary tract and in gonorrhoea much smaller dose is effective. In typhoid fever the consensus of opinion emerging from the accumulated evidences is that an initial loading dose of 50 mg. per kg. of body weight should be followed by 2.5 to -3.0 gm. of the drug daily till the temperature subsides.! The defervescence usually ensues within 2 to 3 days but the drug should be continued for about 10 days or more with gradually reduced doses. Relapses (usually relieved by re-treatment) are not uncommon and in 66 consecutive cases they were found to be about 16 per cent. As high as 50 per cent relapses have also been reported. Smadel emphasized continuation of the drug in 3 gm. daily doses for 10 to 14 days. to prevent relapse. Frequent positive stool culture and development of carrier state even after full treatment are disquieting features.
In chronic carriers with or without infection of gall-bladder this drug is of little avail. Some * A kg., kilogram or kilo is a little over 2 lb.
(2 1/5 lb.) or roughly a seer.
t An allowance of 30 gm. per case should be made, not counting relapses. dreaded complications such as intestinal hemorrhage and perforation, cerebral irritation like encephalitis, may occur in spite of the treatment.
Prolonged treatment for 10 to 15 days to prevent relapse is probably more important than the initial loading dose which is being waived by some workers nowadays. Interrupted treatment with 5 days' regime and 5 days' gap for two/three times has also been suggested.
In typhus group of fever the dosage used is almost the same as in typhoid cases. But the treatment should be continued only till the temperature subsides. Probably smaller doses are effective as found by Giles and Symington (1950) who found an initial dose of 3 gm. was found adequate with further treatment if there is a relapse. Response to Chloromycetin in typhus fever is much more spectacular than in typhoid. Clinical improvement ensues almost immediately following the initial dose.* In experimental cholera in mice, Gauld et al. in 1949 found that the drug is effective against vibrio comma. Chaudhuri et al. (1950) also found that disappearance rate of vibrio in cholera stool of human subjects is very rapid under Chloromycetin therapy.
Combined use of this drug with other antibiotics and chemotherapeutie agents for synergic action particularly in chronic and obstinate infections is under preliminary trial and may yield valuable results. Economic reasons, however, preclude the use of Chloromycetin in most of the bacterial infections susceptible to sulphonamides and penicillin, but the drug may have a place in the treatment of infections by organisms like B. coli and N. gonorrhoea when they are found to be resistant to the common therapeutic agents. H. C. 
